Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 13, 2024

https://www.globenewswire.com/news-release/2024/05/13/2880920/0/en/Allogene-Therapeutics-Announces-Pricing-of-110-million-Offering-of-Common-Stock.html

SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of $2.90 per share. The gross proceeds from this offering are expected to be approximately $110 million, before deducting the underwriting discount and commissions and estimated offering expenses payable by Allogene.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.